[關(guān)鍵詞]
[摘要]
糖尿病心肌病是一種由糖尿病導(dǎo)致的嚴(yán)重并發(fā)癥，尚無(wú)有效的靶向藥物治療策略。糖尿病心肌病早期生物標(biāo)志物對(duì)糖尿病心肌病的早期診斷、降低其導(dǎo)致的死亡率具有重要的臨床意義，對(duì)相關(guān)藥物的研發(fā)和藥效評(píng)價(jià)也具有重要的指導(dǎo)意義。總結(jié)了傳統(tǒng)臨床診斷標(biāo)志物、炎癥相關(guān)標(biāo)志物、心肌纖維化相關(guān)標(biāo)志物、心肌重構(gòu)相關(guān)標(biāo)志物在糖尿病心肌病藥物治療中的應(yīng)用情況，歸納了調(diào)節(jié)生物標(biāo)志物治療糖尿病心肌病的藥物研究進(jìn)展，期望為相關(guān)藥物的藥效評(píng)價(jià)提供參考。
[Key word]
[Abstract]
Diabetic cardiomyopathy is a serious complication caused by diabetes, and there is no effective targeted drug therapy strategy. The early biomarkers of diabetic cardiomyopathy have important clinical significance for the early diagnosis of diabetes cardiomyopathy and the reduction of mortality caused by it, and also have important guiding significance for the development and efficacy evaluation of related drugs. This article summarized the application of traditional clinical diagnostic markers, inflammation related markers, myocardial fibrosis related markers, and myocardial remodeling related markers in the drug treatment of diabetic cardiomyopathy, and summarized the drug research progress of regulating biomarkers in treatment of diabetic cardiomyopathy, hoping to provide reference for the efficacy evaluation of related drugs.
[中圖分類(lèi)號(hào)]
R977
[基金項(xiàng)目]
天津市衛(wèi)健委中醫(yī)、中西醫(yī)結(jié)合科研課題(2023212)
